C2N Diagnostics, Cambridge Isotope Ink Deal Aimed at Accelerating Biomarker Commercialization | GenomeWeb

NEW YORK (GenomeWeb News) – C2N Diagnostics today announced a research and supplier agreement with Cambridge Isotope Laboratories to provide C2N access to large quantities of highly enriched stable isotopes.

C2N uses the isotopes for its Stable Isotope Labeling Kinetic (SILK)-based biomarkers, which it said has the potential for use in the early detection of Alzheimer's well before clinical symptoms are evident. They also show promise as measurement tools for determining treatment response in preclinical and clinical drug studies, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.